- Home
- NRXP vs RLMD Comparison
NRXP vs RLMD Comparison
Compare NRXP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- RLMD
- Stock Information
- Founded
- NRXP 2015
- RLMD 2004
- Country
- NRXP United States
- RLMD United States
- Employees
- NRXP N/A
- RLMD N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- RLMD Health Care
- Exchange
- NRXP Nasdaq
- RLMD Nasdaq
- Market Cap
- NRXP 58.5M
- RLMD 52.8M
- IPO Year
- NRXP N/A
- RLMD N/A
- Fundamental
- Price
- NRXP $3.05
- RLMD $1.66
- Analyst Decision
- NRXP Strong Buy
- RLMD Buy
- Analyst Count
- NRXP 5
- RLMD 3
- Target Price
- NRXP $31.40
- RLMD $5.00
- AVG Volume (30 Days)
- NRXP 498.6K
- RLMD 1.8M
- Earning Date
- NRXP 11-13-2025
- RLMD 11-06-2025
- Dividend Yield
- NRXP N/A
- RLMD N/A
- EPS Growth
- NRXP N/A
- RLMD N/A
- EPS
- NRXP N/A
- RLMD N/A
- Revenue
- NRXP N/A
- RLMD N/A
- Revenue This Year
- NRXP N/A
- RLMD N/A
- Revenue Next Year
- NRXP $231.16
- RLMD N/A
- P/E Ratio
- NRXP N/A
- RLMD N/A
- Revenue Growth
- NRXP N/A
- RLMD N/A
- 52 Week Low
- NRXP $1.10
- RLMD $0.24
- 52 Week High
- NRXP $6.01
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- NRXP 58.85
- RLMD 70.03
- Support Level
- NRXP $2.91
- RLMD $1.45
- Resistance Level
- NRXP $3.18
- RLMD $1.94
- Average True Range (ATR)
- NRXP 0.24
- RLMD 0.28
- MACD
- NRXP 0.04
- RLMD 0.01
- Stochastic Oscillator
- NRXP 87.19
- RLMD 75.29
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.